AU2001293233A1 - Aza heterocyclic derivatives and their therapeutic use - Google Patents
Aza heterocyclic derivatives and their therapeutic useInfo
- Publication number
- AU2001293233A1 AU2001293233A1 AU2001293233A AU9323301A AU2001293233A1 AU 2001293233 A1 AU2001293233 A1 AU 2001293233A1 AU 2001293233 A AU2001293233 A AU 2001293233A AU 9323301 A AU9323301 A AU 9323301A AU 2001293233 A1 AU2001293233 A1 AU 2001293233A1
- Authority
- AU
- Australia
- Prior art keywords
- sup
- therapeutic use
- heterocyclic derivatives
- pharmaceutically acceptable
- aza heterocyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
Organic compounds having the structural formula I are provided where the variables have the values described herein and R<SUP>1 </SUP>and R<SUP>2 </SUP>join together to form a 6 membered substituted or unsubstituted ring including at least one O, N, or S atom, and Z is an O, S, NH or NR group. Pharmaceutical formulations include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23182900P | 2000-09-01 | 2000-09-01 | |
US60/231,829 | 2000-09-01 | ||
PCT/US2001/041942 WO2002018383A2 (en) | 2000-09-01 | 2001-08-30 | Aza heterocyclic derivatives and their therapeutic use |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001293233A1 true AU2001293233A1 (en) | 2002-03-13 |
Family
ID=22870779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001293233A Abandoned AU2001293233A1 (en) | 2000-09-01 | 2001-08-30 | Aza heterocyclic derivatives and their therapeutic use |
Country Status (9)
Country | Link |
---|---|
US (4) | US6756383B2 (en) |
EP (1) | EP1313734B1 (en) |
JP (2) | JP4341949B2 (en) |
AT (1) | ATE448226T1 (en) |
AU (1) | AU2001293233A1 (en) |
DE (1) | DE60140456D1 (en) |
ES (1) | ES2334641T3 (en) |
PT (1) | PT1313734E (en) |
WO (1) | WO2002018383A2 (en) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60140456D1 (en) | 2000-09-01 | 2009-12-24 | Novartis Vaccines & Diagnostic | AZA HETEROCYCLIC DERIVATIVES AND ITS THERAPEUTIC USE |
US20030028018A1 (en) * | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
EP1849782A1 (en) | 2000-09-11 | 2007-10-31 | Novartis Vaccines and Diagnostics, Inc. | Quinolinone derivatives as tyrosine kinase inhibitors |
US7642278B2 (en) * | 2001-07-03 | 2010-01-05 | Novartis Vaccines And Diagnostics, Inc. | Indazole benzimidazole compounds |
JP2004536113A (en) * | 2001-07-03 | 2004-12-02 | カイロン コーポレイション | Indazole benzimidazole compounds as inhibitors of tyrosine kinase and serine / threonine kinase |
US20050256157A1 (en) * | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
CA2496164C (en) * | 2002-08-23 | 2010-11-09 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
US7825132B2 (en) * | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
EP1545529A4 (en) * | 2002-09-30 | 2010-03-03 | Bristol Myers Squibb Co | Novel tyrosine kinase inhibitors |
BR0316229A (en) * | 2002-11-13 | 2005-10-04 | Chiron Corp | Cancer Treatment Methods and Related Methods |
EP1581539A4 (en) * | 2003-01-03 | 2007-09-19 | Bristol Myers Squibb Co | Novel tyrosine kinase inhibitors |
WO2004069160A2 (en) * | 2003-01-28 | 2004-08-19 | Smithkline Beecham Corporation | Chemical compounds |
EP1608369B1 (en) | 2003-03-28 | 2013-06-26 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
EP2762475A1 (en) * | 2003-11-07 | 2014-08-06 | Novartis Vaccines and Diagnostics, Inc. | Pharmaceutically acceptable salts of quinolinone compounds and their medical use |
FR2862969A1 (en) * | 2003-11-28 | 2005-06-03 | Oreal | PROCESS FOR THE PREPARATION OF NITROGEN-SUBSTITUTED PYRROLIDINYL GROUP PARAPHENYLENEDIAMINE DERIVATIVES AND INTERMEDIATE COMPOUNDS |
CN1960731B (en) * | 2004-02-20 | 2011-12-07 | 诺华疫苗和诊断公司 | Method for regulating inflammatory and metastatic processes |
US20060183750A1 (en) | 2005-01-27 | 2006-08-17 | Chiron Corporation | Treatment of metastasized tumors |
NZ597685A (en) | 2005-02-18 | 2013-12-20 | Novartis Vaccines & Diagnostic | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
EP1858919B1 (en) | 2005-02-18 | 2012-04-04 | Novartis Vaccines and Diagnostics, Inc. | Immunogens from uropathogenic escherichia coli |
DK1885187T3 (en) | 2005-05-13 | 2013-12-09 | Novartis Ag | Method of Treating Drug-Resistant Cancer |
AU2006247062A1 (en) | 2005-05-17 | 2006-11-23 | Novartis Ag | Methods for synthesizing heterocyclic compounds |
CA2609353C (en) * | 2005-05-23 | 2015-04-28 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
CA2615626A1 (en) | 2005-07-18 | 2007-01-25 | Novartis Ag | Small animal model for hcv replication |
US7915286B2 (en) | 2005-09-16 | 2011-03-29 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
JP2009514839A (en) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | Adjuvant influenza vaccine containing cytokine inducer |
AU2006310163B2 (en) | 2005-11-04 | 2011-09-15 | Seqirus UK Limited | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
CN102727885A (en) | 2005-11-04 | 2012-10-17 | 诺华疫苗和诊断有限公司 | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
CA2628152C (en) | 2005-11-04 | 2016-02-02 | Novartis Vaccines And Diagnostics S.R.L. | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
MY148529A (en) | 2005-11-29 | 2013-04-30 | Novartis Ag | Formulations of quinolinones |
WO2007067968A2 (en) | 2005-12-08 | 2007-06-14 | Novartis Ag | Effects of inhibitors of fgfr3 on gene transcription |
CA2640248A1 (en) | 2006-01-27 | 2007-08-02 | Novartis Vaccines And Diagnostics Gmbh & Co Kg. | Influenza vaccines containing hemagglutinin and matrix proteins |
ES2376492T3 (en) | 2006-03-23 | 2012-03-14 | Novartis Ag | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS. |
CA2646349A1 (en) | 2006-03-24 | 2007-10-04 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Storage of influenza vaccines without refrigeration |
US20100285062A1 (en) | 2006-03-31 | 2010-11-11 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
PL2054431T3 (en) | 2006-06-09 | 2012-07-31 | Novartis Ag | Conformers of bacterial adhesins |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
GB0614471D0 (en) | 2006-07-20 | 2006-08-30 | Syngenta Ltd | Herbicidal Compounds |
WO2008020330A2 (en) | 2006-08-16 | 2008-02-21 | Novartis Ag | Immunogens from uropathogenic escherichia coli |
EP3456348A1 (en) | 2006-09-11 | 2019-03-20 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
PT2121011E (en) | 2006-12-06 | 2014-07-31 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
CA2692200A1 (en) | 2007-06-27 | 2008-12-31 | Novartis Ag | Low-additive influenza vaccines |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
GB0800855D0 (en) * | 2008-01-17 | 2008-02-27 | Syngenta Ltd | Herbicidal compounds |
EP2889042A3 (en) | 2008-03-18 | 2015-10-14 | Novartis AG | Improvements in preparation of influenza virus vaccine antigens |
JP2012519482A (en) | 2009-03-06 | 2012-08-30 | ノバルティス アーゲー | Chlamydia antigen |
SI2510947T1 (en) | 2009-04-14 | 2016-05-31 | Glaxosmithkline Biologicals S.A. | Compositions for immunising against Staphylococcus aureus |
BE1019643A3 (en) | 2009-04-27 | 2012-09-04 | Novartis Ag | INFLUENZA PROTECTION VACCINES. |
SG177533A1 (en) | 2009-07-07 | 2012-02-28 | Novartis Ag | Conserved escherichia coli immunogens |
HRP20220756T1 (en) | 2009-07-15 | 2022-09-02 | Glaxosmithkline Biologicals S.A. | Rsv f protein compositions and methods for making same |
CN102770443A (en) | 2009-07-16 | 2012-11-07 | 诺华有限公司 | Detoxified escherichia coli immunogens |
GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
WO2011051212A1 (en) * | 2009-10-28 | 2011-05-05 | Basf Se | Use of heteroaromatic compounds as herbicides |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
JP5781542B2 (en) | 2009-12-30 | 2015-09-24 | ノバルティス アーゲー | E. polysaccharide immunogen conjugated to an E. coli carrier protein |
CN102933267B (en) | 2010-05-28 | 2015-05-27 | 泰特里斯在线公司 | Interactive hybrid asynchronous computer game infrastructure |
GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
EP4144368A1 (en) | 2011-01-26 | 2023-03-08 | GlaxoSmithKline Biologicals S.A. | Rsv immunization regimen |
US20140248314A1 (en) | 2011-05-13 | 2014-09-04 | Novartis Ag | Pre-fusion rsv f antigens |
AU2012267556B9 (en) | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
JP6088507B2 (en) | 2011-07-08 | 2017-03-01 | ノバルティス アーゲー | Tyrosine ligation method |
JP6170932B2 (en) | 2011-11-07 | 2017-07-26 | ノバルティス アーゲー | Carrier molecule comprising spr0096 antigen and spr2021 antigen |
WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
KR20150060986A (en) | 2012-10-02 | 2015-06-03 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Nonlinear saccharide conjugate |
EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
EP2977374A1 (en) | 2014-07-21 | 2016-01-27 | Université de Strasbourg | Molecules presenting dual emission properties |
CA2989684A1 (en) * | 2015-06-25 | 2016-12-29 | University Health Network | Hpk1 inhibitors and methods of using same |
CN107935858B (en) * | 2016-10-12 | 2020-09-08 | 利尔化学股份有限公司 | Preparation method of 5-fluoro-2-nitrophenol |
KR20200092987A (en) * | 2017-11-24 | 2020-08-04 | 얀센 파마슈티카 엔.브이. | Pyrazolopyridinone compounds |
WO2019101183A1 (en) * | 2017-11-24 | 2019-05-31 | Janssen Pharmaceutica Nv | Pyrazolopyridinone compounds |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE290153C (en) | ||||
DE2363459A1 (en) | 1973-12-20 | 1975-06-26 | Basf Ag | 7-Amino-quinoline cpds. - for use as optical brighteners, dyes, colour formers in copying and in printing pastes |
DE3634066A1 (en) | 1986-10-07 | 1988-04-21 | Boehringer Mannheim Gmbh | NEW 5-ALKYLBENZIMIDAZOLES, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS |
US5073492A (en) | 1987-01-09 | 1991-12-17 | The Johns Hopkins University | Synergistic composition for endothelial cell growth |
DE3739366A1 (en) | 1987-04-10 | 1988-10-27 | Boehringer Mannheim Gmbh | DESAZA-PURIN-NUCLEOSIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN NUCLEIC ACID SEQUENCING AND AS AN ANTIVIRAL AGENT |
JPH0699497B2 (en) | 1987-04-16 | 1994-12-07 | 富士写真フイルム株式会社 | Photopolymerizable composition |
GB8709448D0 (en) | 1987-04-21 | 1987-05-28 | Pfizer Ltd | Heterobicyclic quinoline derivatives |
DE3932953A1 (en) | 1989-10-03 | 1991-04-11 | Boehringer Mannheim Gmbh | NEW 2-BICYCLO-BENZIMIDAZOLES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
GB9107742D0 (en) | 1991-04-11 | 1991-05-29 | Rhone Poulenc Agriculture | New compositions of matter |
GB9108369D0 (en) | 1991-04-18 | 1991-06-05 | Rhone Poulenc Agriculture | Compositions of matter |
GB9108547D0 (en) | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
DE69222637T2 (en) * | 1991-05-10 | 1998-02-26 | Rhone Poulenc Rorer Int | UP TO MONO AND BICYCLIC ARYL AND HETEROARYL DERIVATIVES WITH INHIBITING EFFECT ON EGF AND / OR PDGF RECEPTOR TYROSINKINASE |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
USRE37650E1 (en) | 1991-05-10 | 2002-04-09 | Aventis Pharmacetical Products, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5856115A (en) | 1991-05-24 | 1999-01-05 | Fred Hutchinson Cancer Research Center | Assay for identification therapeutic agents |
DE4129603A1 (en) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | CONDENSED 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE COMPOUNDS |
AU3737893A (en) | 1992-03-05 | 1993-10-05 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
JP3142378B2 (en) | 1992-06-22 | 2001-03-07 | ティーディーケイ株式会社 | Organic EL device |
US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
US5981569A (en) | 1992-11-13 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease |
US5763441A (en) | 1992-11-13 | 1998-06-09 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
US5792771A (en) | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
JPH0743896A (en) | 1993-07-28 | 1995-02-14 | Toyobo Co Ltd | Photopolymerizable composition |
AU5881394A (en) | 1994-01-08 | 1995-08-01 | Rhone-Poulenc Agriculture Limited | Benzimidazolyl quinoline-3-carboxylate derivatives, intermediates thereto, and their use as herbicides |
JPH0829973A (en) | 1994-07-11 | 1996-02-02 | Toyobo Co Ltd | Photopolymerized composition |
JP3441246B2 (en) | 1995-06-07 | 2003-08-25 | 富士写真フイルム株式会社 | Photopolymerizable composition |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
WO1997034876A1 (en) | 1996-03-15 | 1997-09-25 | Zeneca Limited | Cinnoline derivatives and use as medicine |
DE19610723A1 (en) | 1996-03-19 | 1997-09-25 | Bayer Ag | Electroluminescent devices using glare systems |
US5942385A (en) | 1996-03-21 | 1999-08-24 | Sugen, Inc. | Method for molecular diagnosis of tumor angiogenesis and metastasis |
WO1997048697A1 (en) | 1996-06-19 | 1997-12-24 | Rhone-Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
AU727708B2 (en) | 1996-06-20 | 2000-12-21 | Board Of Regents, The University Of Texas System | Compounds and methods for providing pharmacologically active preparations and uses thereof |
WO1998013350A1 (en) | 1996-09-25 | 1998-04-02 | Zeneca Limited | Qinoline derivatives inhibiting the effect of growth factors such as vegf |
AU8816298A (en) | 1997-08-22 | 1999-03-16 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
DE19756235A1 (en) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | New piperidinyl-substituted pyridylalkane alkene and alkane carboxylic acid amides |
CA2312953A1 (en) * | 1998-03-31 | 1999-10-07 | Warner-Lambert Company | Quinolones as serine protease inhibitors |
WO1999059636A1 (en) | 1998-05-20 | 1999-11-25 | Kyowa Hakko Kogyo Co., Ltd. | Vegf activity inhibitors |
ATE274510T1 (en) | 1998-06-19 | 2004-09-15 | Chiron Corp | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS |
EP1091945A1 (en) | 1998-06-29 | 2001-04-18 | Du Pont Pharmaceuticals Company | Cyclic carbamates and isoxazolidines as iib/iiia antagonists |
FR2781218B1 (en) | 1998-07-15 | 2001-09-07 | Lafon Labor | PHARMACEUTICAL COMPOSITIONS COMPRISING 2-QUINOLONES |
EP1109555A4 (en) * | 1998-08-31 | 2001-11-21 | Merck & Co Inc | Novel angiogenesis inhibitors |
DE19841985A1 (en) | 1998-09-03 | 2000-03-09 | Schering Ag | New heterocyclic alkanesulfonic and alkane carboxylic acid derivatives are VEGF receptor blockers useful in treatment of e.g. psoriasis, rheumatoid arthritis, stroke, tumors and endometriosis |
AU1099000A (en) | 1998-10-05 | 2000-04-26 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions for treating hepatitis c infections |
IL126953A0 (en) | 1998-11-08 | 1999-09-22 | Yeda Res & Dev | Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives |
KR100373203B1 (en) | 1999-03-31 | 2003-02-25 | 주식회사 엘지화학 | New organometallic complexes for use in light emitting devices |
CN1351498B (en) | 1999-05-21 | 2012-08-15 | 布里斯托尔-迈尔斯斯奎布公司 | Pyrrolotriazines inhibitors of kinases |
PE20010306A1 (en) | 1999-07-02 | 2001-03-29 | Agouron Pharma | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE |
KR100681724B1 (en) * | 1999-10-19 | 2007-02-28 | 머크 앤드 캄파니 인코포레이티드 | Tyrosine kinase inhibitors and pharmaceutical compositions comprising the same |
CA2387840A1 (en) * | 1999-10-19 | 2001-04-26 | Scott R. Hambaugh | Tyrosine kinase inhibitors |
JP2003520254A (en) | 2000-01-19 | 2003-07-02 | エス. ジル,パーカッシュ | Methods and compositions relating to antisense VEGF oligonucleotides |
GB0001930D0 (en) | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
WO2001062252A1 (en) | 2000-02-25 | 2001-08-30 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6420382B2 (en) | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6313138B1 (en) | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
DE60140456D1 (en) | 2000-09-01 | 2009-12-24 | Novartis Vaccines & Diagnostic | AZA HETEROCYCLIC DERIVATIVES AND ITS THERAPEUTIC USE |
EP1849782A1 (en) | 2000-09-11 | 2007-10-31 | Novartis Vaccines and Diagnostics, Inc. | Quinolinone derivatives as tyrosine kinase inhibitors |
US20030028018A1 (en) | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
WO2002032861A2 (en) | 2000-10-17 | 2002-04-25 | Merck & Co., Inc. | Orally active salts with tyrosine kinase activity |
JP2004536113A (en) | 2001-07-03 | 2004-12-02 | カイロン コーポレイション | Indazole benzimidazole compounds as inhibitors of tyrosine kinase and serine / threonine kinase |
CA2496164C (en) | 2002-08-23 | 2010-11-09 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
EP1545529A4 (en) | 2002-09-30 | 2010-03-03 | Bristol Myers Squibb Co | Novel tyrosine kinase inhibitors |
BR0316229A (en) | 2002-11-13 | 2005-10-04 | Chiron Corp | Cancer Treatment Methods and Related Methods |
EP1608369B1 (en) | 2003-03-28 | 2013-06-26 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
US6774327B1 (en) | 2003-09-24 | 2004-08-10 | Agilent Technologies, Inc. | Hermetic seals for electronic components |
EP2762475A1 (en) | 2003-11-07 | 2014-08-06 | Novartis Vaccines and Diagnostics, Inc. | Pharmaceutically acceptable salts of quinolinone compounds and their medical use |
WO2005053692A1 (en) | 2003-12-01 | 2005-06-16 | The Scripps Research Institute | Advanced quinolinone based protein kinase inhibitors |
US20060183750A1 (en) | 2005-01-27 | 2006-08-17 | Chiron Corporation | Treatment of metastasized tumors |
-
2001
- 2001-08-30 DE DE60140456T patent/DE60140456D1/en not_active Expired - Lifetime
- 2001-08-30 AU AU2001293233A patent/AU2001293233A1/en not_active Abandoned
- 2001-08-30 PT PT01973678T patent/PT1313734E/en unknown
- 2001-08-30 AT AT01973678T patent/ATE448226T1/en not_active IP Right Cessation
- 2001-08-30 ES ES01973678T patent/ES2334641T3/en not_active Expired - Lifetime
- 2001-08-30 JP JP2002523898A patent/JP4341949B2/en not_active Expired - Fee Related
- 2001-08-30 EP EP01973678A patent/EP1313734B1/en not_active Expired - Lifetime
- 2001-08-30 US US09/943,382 patent/US6756383B2/en not_active Expired - Fee Related
- 2001-08-30 WO PCT/US2001/041942 patent/WO2002018383A2/en active Application Filing
-
2003
- 2003-06-02 US US10/452,786 patent/US6759417B2/en not_active Expired - Fee Related
-
2004
- 2004-04-14 US US10/823,995 patent/US7138409B2/en not_active Expired - Fee Related
-
2006
- 2006-10-11 US US11/546,814 patent/US7368459B2/en not_active Expired - Fee Related
-
2007
- 2007-05-16 JP JP2007131084A patent/JP2007217427A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2002018383A2 (en) | 2002-03-07 |
US20050137188A1 (en) | 2005-06-23 |
US6759417B2 (en) | 2004-07-06 |
US20070032528A1 (en) | 2007-02-08 |
JP2004507543A (en) | 2004-03-11 |
DE60140456D1 (en) | 2009-12-24 |
JP2007217427A (en) | 2007-08-30 |
EP1313734B1 (en) | 2009-11-11 |
US20040002518A1 (en) | 2004-01-01 |
EP1313734A2 (en) | 2003-05-28 |
PT1313734E (en) | 2010-02-09 |
US7138409B2 (en) | 2006-11-21 |
JP4341949B2 (en) | 2009-10-14 |
US7368459B2 (en) | 2008-05-06 |
US20020103230A1 (en) | 2002-08-01 |
ATE448226T1 (en) | 2009-11-15 |
WO2002018383A3 (en) | 2002-08-29 |
ES2334641T3 (en) | 2010-03-15 |
US6756383B2 (en) | 2004-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001293233A1 (en) | Aza heterocyclic derivatives and their therapeutic use | |
TR200200579T2 (en) | Amino-thyrazolpyridine derivatives. | |
YU69902A (en) | New piperazine derivatives | |
BG103945A (en) | Derivatives of 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a | |
WO2003013484A3 (en) | N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents | |
DE69528005T2 (en) | Prolineamid derivatives | |
DE69933573D1 (en) | CHINAZOLINE DERIVATIVES AS MEDICAMENTS | |
ES2147836T3 (en) | DERIVATIVES OF 4,5-DIARILOXAZOLE. | |
AP9801378A0 (en) | 9-amino-3- keto erythromycin derivatives. | |
EP0386675A3 (en) | Xanthine derivatives | |
KR960701878A (en) | Water-soluble camptothecin derivatives, process for their preparation and their use as antitumor agents | |
AU1247195A (en) | Cyclic amide derivatives as neurokinin a antagonists | |
CA2386813A1 (en) | Bicyclic imidazo-3-yl amine derivatives substituted on the 6-membered ring | |
YU30603A (en) | Bridged piperazine derivatives | |
MY133112A (en) | 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use | |
FI101227B1 (en) | Process for the preparation of pharmaceutically active 4-deoxy-4-epipodophyllotoxin derivatives | |
AP9801377A0 (en) | Tricyclic erythromycin derivatives. | |
MXPA02004441A (en) | Isoxazole derivatives to be used as phosphodiesterase vii inhibitors. | |
DE69330601D1 (en) | SEROTON INERGIC ERGOLIN DERIVATIVES | |
WO2001017955A3 (en) | Hydroxyacetamidobenzenesulphonamide derivatives | |
DE69828390D1 (en) | DIAMINOTRIFLUOROMETHYLPYRIMIDIN DERIVATIVES ANTICREASIC COMPOSITION | |
AP2002002595A0 (en) | Heterocyclic amide derivatives. | |
EP2266566A3 (en) | Nicotinamide derivatives and their use as therapeutic agents | |
DE60021109D1 (en) | AMYCOMYCIN, METHOD FOR ITS PREPARATION AND ITS USE AS A MEDICAMENT | |
TH50555A (en) | Imidazopyridin derivatives as an inhibitor of phosphodysterase VII. |